Robert A. Lippe - 10 Nov 2021 Form 4 Insider Report for Liquidia Corp (LQDA)

Reporting relationship: Chief Operations Officer
Issuer ticker: LQDA
Reported as of: 10 Nov 2021
Net transaction value: -$64,391
SEC form: 4
Accepted by SEC: 12 Nov 2021, 19:18:05 UTC
Prior SEC filing: 23 Jul 2021
Next SEC filing: 19 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Russell Schundler, as attorney-in-fact for Robert A. Lippe

Key filing fact

Robert A. Lippe filed Form 4 for Liquidia Corp (LQDA) on 12 Nov 2021.

Key facts

This page summarizes Robert A. Lippe's Form 4 filing for Liquidia Corp (LQDA).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Nov 2021, 19:18.

Change

Previous filing in this sequence was filed on 23 Jul 2021.
Current net transaction value: -$64,391.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LQDA transaction

Common Stock

Options Exercise

Transaction value
Shares: +51,250
Change %: +181%
Price
Shares after: 79,610
Date: 10 Nov 2021
Ownership: Direct
Footnotes: F1

LQDA transaction

Common Stock

Tax liability

Transaction value: $61,780
Shares: -12,612
Change %: -16%
Price: $4.90
Shares after: 66,998
Date: 12 Nov 2021
Ownership: Direct

LQDA transaction

Common Stock

Tax liability

Transaction value: $2,611
Shares: -518
Change %: -0.77%
Price: $5.04
Shares after: 66,480
Date: 12 Nov 2021
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LQDA transaction Derivative

Performance Stock Units

Award

Transaction value: $0
Shares: -51,250
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 10 Nov 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 51,250
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each performance stock unit (PSU) converts into one share of common stock of the Issuer.

Footnote F2

On January 19, 2021, the reporting person was granted 51,250 PSUs, vesting in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861.

SEC remarks

Exhibit 24 - Power of Attorney